Entropy Neurodynamics Limited has released a press release.
Appendix 4E Preliminary Final Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- Completion of patient dosing in maiden TRP-8803 trial
- Positive Phase 2a fibromyalgia results across all patients
- Maiden dosing of TRP-8803 completed in global first
- Reinstatement to Quotation
- Results of 2024 General Meeting
Later from Entropy Neurodynamics
- Preliminary Final Report Reporting Adjustments
- TRP-8803 doses deemed safe by SRC following phase 1b study
- Pause in Trading
- $6m funding to fast track TRP-8803 clinical trial strategy
- Phase 1b determines optimal parameters for TRP-8803 use
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics